奥科 AUDC 深 沪
已收盘 02-06 16:00:00 美东时间
7.64
+0.180
+2.41%
华盛通- 最 高7.72
- 今 开7.42
- 成交量 20.55万股
- 最 低 7.42
- 昨 收 7.46
- 总市值 2.19亿
- 52周最高 11.90
- 市盈率 静 24.72
- 换手率 0.72%
- 52周最低 7.22
- 委 比 -65.61%
- 总股本 2867.72万
- 历史最高 43.01
- 量 比 0.80
- 振 幅 4.02%
- 历史最低 -1.29
- 每 手 1
- 风险率 0.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多AudioCodes Adopts Rule 10b5-1 Plan to Sustain Share Repurchases
Audiocodes ( ($AUDC) ) has provided an update. On February 4, 2026, AudioCodes ...
02-05 02:47
AudioCodes Sees FY2026 Adj EPS $0.60-$0.75 vs $0.67 Est; Sees Sales $247.000M-$255.000M vs $252.800M Est
AudioCodes (NASDAQ:AUDC) is looking for FY2026 Adj EPS of $0.60-$0.75 vs $0.67 analyst estimate. sees sales of $247.000 million-$255.000 million vs $252.800 million analyst estimate.
02-04 06:50
AudioCodes shares are trading lower. The company reported Q4 financial results.
AudioCodes shares are trading lower. The company reported Q4 financial results.
02-04 03:31
Earnings Scheduled For February 3, 2026
Companies Reporting Before The Bell • Atkore (NYSE:ATKR) is expected to report ...
02-03 19:11
AudioCodes Q4 Adj. EPS $0.16, Inline, Sales $62.605M Beat $62.200M Estimate
AudioCodes (NASDAQ:AUDC) reported quarterly earnings of $0.16 per share which met the analyst consensus estimate. This is a 56.76 percent decrease over earnings of $0.37 per share from the same period last year. The
02-03 15:09
AudioCodes Expands Certified Portfolio Of Voice Solutions For Webex Calling, Cisco's Cloud-Based Unified Communications Platform
AudioCodes (NASDAQ:AUDC), a global leader in enterprise voice and VoiceAI business solutions, today announced that it has expanded its certified portfolio of voice solutions for Webex Calling, Cisco's cloud-based unified
02-02 22:14
AudioCodes Expands Its Voice Solution Portfolio for Webex Calling
AudioCodes now offers an end-to-end portfolio of certified voice solutions for Webex Calling, from Cloud Connect PSTN connectivity to analog gateways and desk phones OR YEHUDA, Israel, Feb. ...
02-02 22:00
已商业化！“奥科达-B”首次递表，产品已获FDA批准，销售收入增速超46%
奥科达于2026年1月26日向港交所递交招股书，拟在香港主板上市，联席保荐人为招商证券及建银国际。公司为一家研发驱动型特色制药企业，专注于中枢神经系统疾病、代谢性疾病及罕见病等领域的创新药物研发。2025年前九个月收入约1.86亿人民币，同比下滑10.36%，净亏损0.40亿人民币。公司旗舰产品Motpoly XR™为全球唯一 FDA批准的每日一次缓释拉考沙胺。中枢神经系统药物市场稳步增长，奥科达产品具备竞争优势。主要股东李守峰博士持有29.83%股份，管理层由李守峰博士担任CEO。
01-27 17:32
奥科达医药递表港交所
新京报贝壳财经讯 1月26日，据港交所文件披露，上海奥科达医药科技股份有限公司（简称“奥科达医药”）向港交所主板递交上市申请书，招商证券国际、建银国际为其联席保...
01-27 12:26
新股消息 | 奥科达医药递表港交所
据港交所1月26日披露，上海奥科达医药科技股份有限公司(简称：奥科达医药)向港交所主板递交上市申请书，招商证券国际、建银国际为其联席保荐人。
01-27 07:35
